6月8日，科伦博泰生物盘中下跌3.15%，报381.8港元，成交额5525.37万港元。
消息面上，港交所披露显示，董事长刘革新近期持续减持公司股份，自5月26日以来已累计多次卖出，其中6月1日减持17.92万股、6月3日减持10.36万股、6月4日减持7.06万股，减持节奏密集，持续加重市场抛压情绪。此外，公司此前披露的业绩显示，尽管营收增长6.5%至20.58亿元，但净亏损扩大至3.82亿元，授权及里程碑收入大幅减少、研发费用高企为主要拖累。尽管公司已发布回购授权计划并在ASCO大会获得重磅临床数据支撑，但董事长连续减持信号仍对短期市场信心构成压制。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.